Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 70%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 57% · prior close shown (market closed)
Editas Medicine, Inc. shows accelerating business momentum based on AlphaOS pipeline evidence.
Why it matters: Revenue +232% YoY in Q2 FY2026.
4 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 1d ago
Reported figures for Editas Medicine, Inc. — research only, not investment advice.
Updated
What happened recently for Editas Medicine, Inc. (EDIT) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
Prior close
$2.81
Market cap
$431.56M
Profitable
No
Revenue $2.83M
Net income
$-24.98M
FY Jul 17, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Editas Medicine, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Connected companies and research pages from the AlphaOS knowledge graph.
Follow Editas Medicine, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.